Related Experiment Video
Updated: Aug 8, 2026

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
Published on: December 28, 2015
Abnormal patterns of immunoglobulin heavy chain gene DNA fingerprinting during chronic phase chronic myeloid leukemia
A Spencer1, R Szydlo, F H Grand
1Haematology Department, Mater Hospital, Newcastle, Australia. andrewspencer@hunterlink.net.au
Insights
Abnormal immunoglobulin heavy chain (IgH) DNA fingerprints are common in chronic myeloid leukemia (CML) and may predict blast crisis. Interferon-alpha (IFN) therapy was associated with normal IgH fingerprints in CML patients.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Background:
- Clonal immunoglobulin heavy chain (IgH) gene rearrangements are observed in chronic phase (CP) chronic myeloid leukemia (CML) patients who progress to lymphoid blast crisis (L-BC).
- Understanding the frequency and implications of these rearrangements is crucial for predicting disease progression.
Purpose of the Study:
- To determine the frequency of abnormal IgH DNA fingerprints in CP CML patients.
- To investigate the relationship between IgH fingerprint patterns and treatment regimens, particularly interferon-alpha (IFN).
- To assess the predictive value of IgH fingerprints for impending blast crisis in CML.
Main Methods:
- A cohort of 33 CP CML patients was monitored over 16 months.
- IgH DNA fingerprinting, using PCR amplification of the IgH gene's third complementarity determining region (CDR3) and polyacrylamide gel electrophoresis, was performed on 111 occasions.
- Patients received either IFN-containing or non-IFN-containing regimens, or variable therapy.
Main Results:
- Abnormal IgH fingerprints were detected in 26% (29/111) of analyzed specimens.
- Patients receiving IFN-containing regimens consistently showed normal IgH fingerprints, while 10 of 15 patients on non-IFN regimens exhibited abnormalities (p = 0.00023).
- Abnormal fingerprints correlated with elevated peripheral blood lymphocyte counts (p = 0.0001) and preceded the diagnosis of L-BC by 7 months in one patient.
Conclusions:
- Abnormal IgH fingerprints are prevalent in CP CML patients.
- Interferon-alpha (IFN) therapy is associated with the maintenance of normal IgH DNA fingerprints in CML.
- Detection of abnormal IgH fingerprints may serve as a valuable predictor for the lineage of impending blast crisis in CML.
Abstract:
Using IgH DNA fingerprinting we have previously demonstrated clonal immunoglobulin heavy chain (IgH) gene rearrangements during chronic phase (CP) chronic myeloid leukemia (CML) in patients destined to develop lymphoid blast crisis (L-BC). In view of this we decided to follow a cohort of CP CML patients to determine the frequency with which abnormal IgH fingerprints are found and their relationship, if any, to treatment regimen. Thirty three, initially CP, CML patients were studied on 111 occasions over a 16 month period using consensus PCR amplification of the third complementarity determining region (CDR3) of the IgH gene and high resolution polyacrylamide gel electrophoresis (IgH DNA fingerprinting). Of these 33 patients, thirteen received interferon-alpha (IFN) containing regimens and 15 non-IFN containing regimens throughout the study period. Five patients received variable therapy. During the period of observation 7 patients experienced disease progression: 5 accelerated phase, I L-BC and I myeloid blast crisis (M-BC). Abnormal IgH fingerprints were seen in 29 of the 111 (26%) specimens analysed. The 28 patients who received uniform therapy (IFN or non-IFN) over the 16 months were classified as "normal" (n = 18, normal pattern on all occasions) or "abnormal" (n = 10, abnormal on 1 or more occasions). Analysis by patient group (normal vs abnormal) showed that fingerprint abnormalities were associated with an elevated peripheral blood lymphocyte count (p = 0.0001) but not with changes in the total white cell count. Comparison of the IFN vs. non-IFN groups showed the former all had normal patterns whereas 10 of 15 non-IFN therapy patients were abnormal (p = 0.00023). The peripheral blood lymphocyte counts in the normal vs abnormal patients within the non-IFN group were not significantly different. The patient who developed L-BC demonstrated a persistent IgH fingerprint pattern abnormality from 7 months prior to the diagnosis of L-BC. The M-BC patient had a normal pattern at all times. We conclude that: (1) abnormal IgH fingerprints are found in a significant number of CP CML patients; (2) in this cohort the use of IFN was associated with normal CP CML IgH fingerprints, and (3) detection of abnormal IgH fingerprints may be highly predictive for the lineage of impending blast crisis.
More Related Videos
13:21Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients
Published on: June 16, 2017
09:02Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018